NAV

Pyruvaldehyde

Targets (1)

Identification

Name
Pyruvaldehyde
Accession Number
DB03587
Description

An organic compound used often as a reagent in organic synthesis, as a flavoring agent, and in tanning. It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated cell preparations, in various culture media, and in vivo in certain animals. [PubChem]

Type
Small Molecule
Groups
Experimental
Structure
Thumb
3D
Similar Structures
Weight
Average: 72.0627
Monoisotopic: 72.021129372
Chemical Formula
C3H4O2
Synonyms
  • 2-ketopropionaldehyde
  • 2-oxopropanal
  • Acetyl formaldehyde
  • Acetylformyl
  • alpha-ketopropionaldehyde
  • Methyl glyoxal
  • Methylglyoxal
  • Pyruvic aldehyde
External IDs
  • FEMA NO. 2969
  • NSC-337790
  • NSC-626580
  • NSC-79019

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UPhospholipase A2Not AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
Non-Ketotic HyperglycinemiaDisease
SarcosinemiaDisease
Spermidine and Spermine BiosynthesisMetabolic
Dihydropyrimidine Dehydrogenase Deficiency (DHPD)Disease
Dimethylglycine Dehydrogenase DeficiencyDisease
Dimethylglycine Dehydrogenase DeficiencyDisease
Hyperglycinemia, Non-KetoticDisease
Pyruvate Kinase DeficiencyDisease
3-Phosphoglycerate Dehydrogenase DeficiencyDisease
Glycine and Serine MetabolismMetabolic
Pyruvate MetabolismMetabolic
Leigh SyndromeDisease
Pyruvate Dehydrogenase Complex DeficiencyDisease
Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency)Disease
Pyruvaldehyde DegradationMetabolic
Primary Hyperoxaluria II, PH2Disease
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Unlock Additional Data
Calcium carbimideThe risk or severity of adverse effects can be increased when Calcium carbimide is combined with Pyruvaldehyde.
DisulfiramThe risk or severity of adverse effects can be increased when Disulfiram is combined with Pyruvaldehyde.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alpha ketoaldehydes. These are organic compounds containing an aldehyde substituted with a keto group on the adjacent carbon.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Alpha ketoaldehydes
Alternative Parents
Ketones / Short-chain aldehydes / Organic oxides / Hydrocarbon derivatives
Substituents
Aliphatic acyclic compound / Alpha-ketoaldehyde / Hydrocarbon derivative / Ketone / Organic oxide / Short-chain aldehyde
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
propanals, 2-oxo aldehyde (CHEBI:17158) / a ketoaldehyde (METHYL-GLYOXAL)

Chemical Identifiers

UNII
722KLD7415
CAS number
78-98-8
InChI Key
AIJULSRZWUXGPQ-UHFFFAOYSA-N
InChI
InChI=1S/C3H4O2/c1-3(5)2-4/h2H,1H3
IUPAC Name
2-oxopropanal
SMILES
CC(=O)C=O

References

General References
Not Available
Human Metabolome Database
HMDB0001167
KEGG Compound
C00546
PubChem Compound
880
PubChem Substance
46509036
ChemSpider
857
RxNav
1373350
ChEBI
17158
ChEMBL
CHEMBL170721
ZINC
ZINC000001532681
Wikipedia
Methylglyoxal

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility180.0 mg/mLALOGPS
logP-0.38ALOGPS
logP0.2ChemAxon
logS0.4ALOGPS
pKa (Strongest Acidic)16.38ChemAxon
pKa (Strongest Basic)-8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area34.14 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity17.05 m3·mol-1ChemAxon
Polarizability6.42 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.994
Blood Brain Barrier+0.9794
Caco-2 permeable+0.5598
P-glycoprotein substrateNon-substrate0.8244
P-glycoprotein inhibitor INon-inhibitor0.8567
P-glycoprotein inhibitor IINon-inhibitor0.8911
Renal organic cation transporterNon-inhibitor0.9244
CYP450 2C9 substrateNon-substrate0.8232
CYP450 2D6 substrateNon-substrate0.919
CYP450 3A4 substrateNon-substrate0.7631
CYP450 1A2 substrateNon-inhibitor0.8997
CYP450 2C9 inhibitorNon-inhibitor0.9385
CYP450 2D6 inhibitorNon-inhibitor0.9613
CYP450 2C19 inhibitorNon-inhibitor0.9413
CYP450 3A4 inhibitorNon-inhibitor0.9845
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9522
Ames testAMES toxic0.8289
CarcinogenicityCarcinogens 0.588
BiodegradationReady biodegradable0.9186
Rat acute toxicity2.0227 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9636
hERG inhibition (predictor II)Non-inhibitor0.9721
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)LC-MS/MSsplash10-00dj-9000000000-964129275940a60a617d
MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)LC-MS/MSsplash10-006y-9000000000-0ae1e5fd2d50b28f967c
MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)LC-MS/MSsplash10-00dj-9000000000-964129275940a60a617d
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-9000000000-110d6fcd891f2c54a2cb
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-05fr-9000000000-bec3651f9ea6825cf4f7
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-8db5b1ba128748e220c3
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-9000000000-f968a2358e6fd85ae268
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-9000000000-0797bdeaa575b54943c5
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0uk9-9000000000-89ef1c082b2ef672eb67

Targets

Details1. Phospholipase A2
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Receptor binding
Specific Function
PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides, this releases glycerophospholipids and arachidonic acid that serve as the precursors of signal molecules.
Gene Name
PLA2G1B
Uniprot ID
P04054
Uniprot Name
Phospholipase A2
Molecular Weight
16359.535 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on June 12, 2020 10:52

104